Clinical trials: Amyloid Cardiomyopathy
Cardiac Amyloidosis
Individualized Exercise Training in Cardiac Amyloidosis
Numerous clinical trials have demonstrated that transthyretin (TTR)-directed medical therapies can reduce the rate of functional decline in patients with transthyretin cardiac amyloidosis (ATTR-CM).
- Trial name
- GET-FIT ATTR (NCT07835867)
- Testing
- Exercise Intervention, Physical Activity Handout
- Volunteers
- 60 people
- Sponsor
- Oregon Health and Science University
Danon Disease, Fabry Disease
Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques
What is this study about? This research is focused on improving the care for people with rare heart muscle diseases, known as rare cardiomyopathies.
- Conditions
- Danon Disease, Fabry Disease, Cardiac Amyloidosis, Noonan Syndrome
- Trial name
- NCT07336394
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Amyloid Cardiomyopathy
Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy
This Phase 1b/2a study aims to investigate the safety and efficacy of genistein in patients with Transthyretin (TTR) Amyloidosis.
- Trial name
- GASPAR (NCT06634108)
- Testing
- Genistein
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Amyloidosis
The Effect of Diflunisal on Familial Transthyretin Amyloidosis
An ongoing trial of diflunisal has been closed for enrollment, thus, patients suitable for the study can no longer participate or receive treatment by diflunisal; and patients, who have participated in the trial can not continue…
- Trial name
- DFNS01 (NCT01432587)
- Testing
- Diflunisal
- Where
- 3 sites in Sweden
- Volunteers
- 55 people
- Sponsor
- Umeå University
Transthyretin Cardiomyopathy (TTR-CM), Transthyretin (TTR) Amyloid Cardiomyopathy
PL_GNT01_ISR_Grant 53234273
We carry out a prospective non-interventional, longitudinal, observational multicentre registry designed to improve our understanding of the epidemiology of TTR amyloidosis in our country.
- Conditions
- Transthyretin Cardiomyopathy (TTR-CM), Transthyretin (TTR) Amyloid Cardiomyopathy, Transthyretin Amyloidosis
- Trial name
- NCT06714019
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Cardiac Amyloidosis
Cardiac Amyloidosis Discovery Trial
This is a single center, diagnostic clinical trial in which the investigators aim to prospectively validate a deep learning model that identifies patients with features suggestive of cardiac amyloidosis, including transthyretin…
- Trial name
- NCT06469372
- Testing
- Cardiac amyloidosis deep learning model
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Pierre Elias
Amyloidosis Cardiac, Aortic Stenosis, Severe
Analysis of Calcium Score of Severe Aortic Stenosis in Patients With and Without Cardiac Amyloidosis (CAUSATIVE Study)
The concomitant presence of cardiac amyloidosis (CA) in patients with aortic stenosis (AS) may challenge the estimation of stenosis degree.
- Trial name
- CAUSATIVE (NCT06066632)
- Where
- Italy
- Volunteers
- 480 people
- Sponsor
- University Hospital of Ferrara
Amyloidosis, Transthyretin Amyloidosis
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1) Establish the diagnostic accuracy of 124I-evuzumitide in cardiac amyloidosis 2)…
- Trial name
- NCT05758493
- Testing
- 124I-Evuzamitide
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Oregon Health and Science University
Cardiac Amyloidosis
Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography
The primary aim of this pilot study is to determine whether amyloid deposits in the heart can be measured non-invasively by F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET) in 30 individuals with…
- Trial name
- NCT01683825
- Testing
- F-18 florbetapir PET
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Valve Stenoses, Aortic, Amyloidosis Cardiac
Impact of Amyloidosis on TAVI Patients
To analyze the prevalence and impact on the prognosis of amyloidosis due to transthyretin in patients with severe aortic stenosis who undergo percutaneous aortic valve implantation.
- Trial name
- AMY-TAVI (NCT03984877)
- Testing
- Diagnosis of amyloidosis
- Where
- Spain
- Volunteers
- 320 people
- Sponsor
- Javier López Pais
Amyloid, Cardiac Amyloidosis
Pan-Amyloid PET/CT in Various Amyloid-Related Disease
To evaluate the potential usefulness of 18F-92/AV45/TPZA/FT8, 11C-PIB positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Pan-Amyloid-related disease patients.
- Conditions
- Amyloid, Cardiac Amyloidosis, Amyloidosis
- Trial name
- NCT07130565
- Testing
- 18F-92/AV45/TPZA/FT8, 11CPIB
- Where
- 3 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Non-ischemic Cardiomyopathy, DCM - Dilated Cardiomyopathy
DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies
The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical and molecular studies on cardiomyopathies (CMP).
- Conditions
- Non-ischemic Cardiomyopathy, DCM - Dilated Cardiomyopathy, HCM - Hypertrophic Cardiomyopathy, HOCM - Hypertrophic Obstructive Cardiomyopathy
- Trial name
- TORCH-Plus (NCT04265040)
- Where
- Germany
- Volunteers
- 2,040 people
- Sponsor
- University Hospital Heidelberg
Cardiomyopathies, Amyloidosis Cardiac
Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation
The study aims to identify new diagnostic and prognostic markers for CMP that can help predict disease progression. In particular, the study will focus on microRNAs (miRNAs) and spatial transcriptomics, which are emerging…
- Conditions
- Cardiomyopathies, Amyloidosis Cardiac, Fabry Disease, Arrhythmogenic Cardiomyopathy
- Trial name
- CMPMIRNA (NCT06813443)
- Where
- 3 sites in Italy
- Volunteers
- 700 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Transthyretin Amyloidosis, Carpal Tunnel Syndrome
Systemic Transthyretin Amyloidosis: Carpal Tunnel Syndrome in a Portuguese Population
Systemic transthyretin amyloidosis is an aging-related disorder. It is usually associated with cardiac disease but also extends to other organs.
- Trial name
- CarPoS (NCT05409833)
- Testing
- Synovial biopsy and Cardiac scintigraphy with [99mTc]Tc-DPD
- Where
- 2 sites in Portugal
- Volunteers
- 100 people
- Sponsor
- Universidade do Porto
Cardiac Amyloidosis
Prevalence and Prognosis of Cardiac Amiloidosis in Turkey
Patients with left ventricular hypertrophy are further examined according to an algorithm to check if they have a cardiac amyloidosis
- Trial name
- PAPCAT (NCT04915235)
- Testing
- Algorithm
- Where
- Turkey (Türkiye)
- Volunteers
- 2,087 people
- Sponsor
- Turkish Society of Cardiology
Amyloid Cardiomyopathy, Transthyretin-Related
Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations
In this study, the investigators recruited a cohort of elderly Black and Hispanic patients with heart failure to define the number of patients who have cardiac amyloidosis by utilizing highly sensitive heart imaging and blood…
- Trial name
- SCAN-MP (NCT03812172)
- Testing
- 99mTc-PYP or 99m Tc-HDP
- Where
- 4 sites in United States
- Volunteers
- 646 people
- Sponsor
- Mathew S. Maurer, MD
Amyloidosis; Heart (Manifestation), Senile Cardiac Amyloidosis
Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy
The objective of the study is to determine whether the combination of the bile acid TUDCA, and doxycycline will slow the progression of familial and senile amyloidosis.
- Trial name
- NCT01855360
- Testing
- Tauroursodeoxycholic Acid and Doxycycline
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Brigham and Women's Hospital
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
The purpose of this randomised, double-blind, placebo-controlled, multicenter study is to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants…
- Trial name
- ATTRiumph (NCT07608354)
- Testing
- Eplontersen, ALXN2220
- Where
- 76 sites in United States, Canada and 8 more
- Volunteers
- 326 people
- Sponsor
- AstraZeneca
Amyloid Cardiomyopathy, Transthyretin-Related
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
- Trial name
- AG10 (NCT04988386)
- Testing
- Acoramidis (AG10)
- Where
- 72 sites in United States, Australia and 15 more
- Volunteers
- 389 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Heart Failure
CCM OPEN HF Registry
The registry has been designed to evaluate the long-term safety and efficacy of CCM therapy in a real-world setting.
- Trial name
- CCM OPEN HF (NCT07112924)
- Where
- 28 sites in United States
- Volunteers
- 5,500 people
- Sponsor
- Impulse Dynamics